MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury

This potential treatment opportunity was confirmed by the company’s bioinformatics platform, PsyCollage VANCOUVER, BC, March 4, 2021 /CNW/…

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research

The Company expects to have ibogaine manufactured and in use for research by Q4. VANCOUVER, BC, March…

MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin

The completed equity investment strengthens ties between MINDCURE and ATMA VANCOUVER, BC, March 2, 2021 /CNW/ – Mind…

Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors

The appointment further strengthens the Company’s leadership position in the use of technology to develop psychedelic-related…

MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform

MINDCURE’s first items in a line of original supplements, including Reishi Energy, Lion’s Mane Focus, Turkey Tail Immunity, and Teen,…

Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics

Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Englebrings years of understanding of psychedelic medicine into research…

MINDCURE’s Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization

MINDCURE’s PsyCollage tool to drive decision-making for drug lead optimization and assist in the discovery of target receptors. …

MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category

MINDCURE’s proprietary line of integrative medicines, intended to balance the immune system and neurochemicals before and…

Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy

The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic…

Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research

Mind Cure’s iSTRYM (pronounced eye-stream) has been designed to warehouse the largest collection of psychedelic research…

Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club

Mind Cure’s nootropic products are set to launch across 17 locations within North America starting Feb, 2021. VANCOUVER,…

Mind Cure Announces Novel Supplement Product to Address Teen Wellness

Mind Cure announces all-natural supplement designed to relieve restlessness and nervousness in teens, to be released…